My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Merakris Therapeutics

Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
From Merakris Therapeutics
Via GlobeNewswire
International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers
From Merakris Therapeutics
Via GlobeNewswire
2025 CAMPS Summit Selects Merakris Therapeutics’ Scientist with Inaugural “Best Comparative Trial” Award
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Announces Open Enrollment for Phase II Clinical Trial of Subcutaneous Injection Drug for the Treatment of Venous Leg Ulcer
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
From Merakris Therapeutics
Via GlobeNewswire
Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations
From Merakris Therapeutics
Via GlobeNewswire
Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care
From Merakris Therapeutics
Via GlobeNewswire
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
From Merakris Therapeutics
Via GlobeNewswire
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
From Merakris Therapeutics
Via GlobeNewswire
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program
From Merakris Therapeutics
Via GlobeNewswire
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
From Merakris Therapeutics
Via GlobeNewswire
Merakris Announces Review in Biomedicines Medical Journal Highlights Therapeutic Potential of Cell-Free Amniotic Fluid
From Merakris Therapeutics
Via GlobeNewswire
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
From Merakris Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.